Bioeconomy Capital

Bioeconomy Capital is a San Francisco and Seattle-based venture capital firm founded in 2015. The firm focuses on early-stage investments in biotechnology, life sciences, and sustainability technology. Bioeconomy Capital is driven by the goal of accelerating the biotechnology revolution by supporting companies that are developing critical infrastructure and innovative technologies for the 21st century. With a strong foundation in synthetic biology, Bioeconomy Capital leverages decades of expertise in life sciences and engineering to back startups with transformative potential. The firm’s portfolio includes notable companies such as Zymergen, Riffyn, Synthace, RoosterBio, and Arzeda. Bioeconomy Capital typically invests between $100K and $5M, with a sweet spot of $1.5M per investment. The firm has a global focus, primarily investing in the U.S. but occasionally supporting companies in the U.K. and other regions. Led by managing directors Rob Carlson and Rik Wehbring, Bioeconomy Capital plays a strategic role in helping its portfolio companies navigate the complexities of scaling biotech and sustainability solutions​.